Optimizing the concentration and bolus of a drug delivered by continuous infusion

Biometrics

Volumn 67, Issue 4, 2011, Pages 1638-1646

  Thall, Peter F ^a   Szabo, Aniko ^b   Nguyen, Hoang Q ^a   Amlie Lefond, Catherine M ^b   Zaidat, Osama O ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adaptive design; Bayesian design; Clinical trial; Continuous infusion; Phase I II clinical trial; Stroke

Indexed keywords

DRUG DELIVERY; MEDICAL APPLICATIONS;

ADAPTIVE DESIGNS; BAYESIAN DESIGN; CLINICAL TRIAL; CONTINUOUS INFUSIONS; OPTIMAL TREATMENT; PHASE I/II CLINICAL TRIALS; POSTERIOR MEANS; STROKE; THERAPEUTIC EFFICACY; TISSUE PLASMINOGEN ACTIVATOR;

TOXICITY;

BAYESIAN ANALYSIS; CONCENTRATION (COMPOSITION); DATA SET; DESIGN; DRUG; OPTIMIZATION; PHYSIOLOGICAL RESPONSE; STROKE; TOXICITY;

EID: 83655164291     PISSN: 0006341X     EISSN: 15410420     Source Type: Journal    
DOI: 10.1111/j.1541-0420.2011.01580.x     Document Type: Article

References (20)

1. Bekele, B. N. and Shen, Y. (2005). A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics 60, 343-354.
2. Berger, J. O. (1985). Statistical Decision Theory and Bayesian Analysis, 2nd edition. New York: Springer-Verlag.
3. Braun, T. M. (2002). The bivariate continual reassessment method: Extending the CRM to phase I trials of two competing outcomes. Contemporary Clinical Trials 23, 240-256.
4. Braun, T. M., Thall, P. F., Nguyen, H., and de Lima, M. (2007). Simultaneously optimizing dose and schedule of a new cytotoxic agent. Clinical Trials 4, 113-124.
5. deVeber, G., MacGregor, D., Curtis, R., and Mayank, S. (2000). Neurologic outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. Journal of Childhood Neurology 15, 316-324.
6. Gooley, T. A., Martin, P. J., Fisher, L. D., and Pettinger, M. (1994). Simulation as a design tool for phase I/II clinical trials: An example from bone marrow transplantation. Controlled Clinical Trials 15, 450-462.
7. Houede, N., Thall, P. F., Nguyen, H., Paoletti, X., and Kramar, A. (2010). Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials. Biometrics 66, 532-540.
8. Ibrahim, J. G., Chen, M.-H., and Sinha, D. (2001). Bayesian Survival Analysis. New York: Springer.
9. Ivanova, A. (2003). A new dose-finding design for bivariate outcomes. Biometrics 59, 1001-1007.
10. Johnson, S. C., Mendis, S., and Mathers, C. D. (2009). Global variation in stroke burden and mortality: Estimates from monitoring, surveillance, and modelling. The Lancet Neurology 8, 345-354.
11. Kaur, J., Zhao, Z., Klein, G. M., Lo, E. H., and Buchan, A. M. (2004). The neurotoxicity of tissue plasminogen activator? Journal of Cerebral Blood Flow Metabolism 24, 945-963.
12. Khatri, P., Abruzzo, T., Yeatts, S. D., Nichols, C., Broderick, J. P., Tomsick, T. A., and IMS I and II Investigators. (2009). Good clinical outcome after ischemic stroke with successful revascularization is time-dependent. Neurology 73, 1066-1072.
13. O'Quigley, J., Hughes, M. D., and Fenton, T. (2001). Dose-finding designs for HIV studies. Biometrics 57, 1018-1029.
14. Robert, C. P. and Cassella, G. (1999). Monte Carlo Statistical Methods. New York: Springer.
15. Thall, P. F. and Cook, J. D. (2004). Dose-finding based on efficacy-toxicity trade offs. Biometrics 60, 684-693.
16. Thall, P. F. and Russell, K. T. (1998). A strategy for dose finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 54, 251-264.
17. Thall, P. F., Simon, R., and Estey, E. H. (1995). Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 14, 357-379.
18. Thall, P. F., Nguyen, H., and Estey, E. H. (2008). Patient-specific dose-finding based on bivariate outcomes and covariates. Biometrics 64, 1126-1136.
19. Yuan, Y. and Yin, G. (2009). Bayesian dose-finding by jointly modeling toxicity and efficacy as time-to-event outcomes. Journal of the Royal Statistical Society, Series C 58, 954-968.
20. Zhang, W., Sargent, D. J., and Mandrekar, S. (2006). An adaptive dose-finding design incorporating both efficacy and toxicity. Statistics in Medicine 25, 2365-2383.